Patents by Inventor Eike Hoffmann

Eike Hoffmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENERATION OF ANTIBODY-DERIVED POLYPEPTIDES BY POLYPEPTIDE CHAIN EXCHANGE
    Publication number: 20220033525
    Abstract: The present invention relates to a set of heterodimeric polypeptides and its uses, e.g. for generating multispecific antigen binders by polypeptide chain exchange.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Can Martin Buldun, Stefan Dengle, Steffen Dickopf, Guy Georges, Eike Hoffmann, Sabine Imhof-Jung, David Zilian
  • METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
    Publication number: 20200392253
    Abstract: Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Stefan Dengl, Guy Georges, Eike Hoffmann, Klaus Mayer, Felix Bormann
  • COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES
    Publication number: 20200164064
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Application
    Filed: October 29, 2019
    Publication date: May 28, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Ulrich BRINKMANN, Stefan DENGL, Sebastian DZIADEK, Guy GEORGES, Michael GROTE, Alexander HAAS, Eike HOFFMANN
  • TRIVALENT, BISPECIFIC ANTIBODIES
    Publication number: 20200062826
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Rebecca CROASDALE, Eike HOFFMANN, Christian KLEIN, Ekkehard MOESSNER, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
  • Covalently linked antigen-antibody conjugates
    Patent number: 10517945
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 31, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Joerg Benz, Ulrich Brinkmann, Stefan Dengl, Sebastian Dziadek, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann
  • Covalently linked polypeptide toxin-antibody conjugates
    Patent number: 10519249
    Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Eike Hoffmann, Stefan Dengl, Klaus Mayer
  • Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
    Patent number: 10407511
    Abstract: Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Eike Hoffmann, Georg Tiefenthaler, Ekkehard Moessner, Stefan Dengl, Achim Gaertner
  • Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
    Patent number: 10137170
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 27, 2018
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, HOFFMANN-LA ROCHE INC.
    Inventors: Sara Belli, Konrad Bleicher, Richard D. Dimarchi, Eike Hoffmann, Eric A. Kitas, Anish A. Konkar
  • TRIVALENT, BISPECIFIC ANTIBODIES
    Publication number: 20180282399
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: December 28, 2017
    Publication date: October 4, 2018
    Inventors: Ulrich BRINKMANN, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • Anti-theophylline antibodies and methods of use
    Patent number: 9925272
    Abstract: The invention provides anti-theophylline antibodies and methods of using the same.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 27, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Eike Hoffmann
  • Trivalent, bispecific antibodies
    Patent number: 9890204
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • Anti-biotin antibodies and methods of use
    Patent number: 9765153
    Abstract: The invention provides anti-biotin antibodies and methods of using the same.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 19, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Guy Georges, Michael Grote, Eike Hoffmann
  • COVALENTLY LINKED HELICAR-ANTI-HELICAR ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20170058050
    Abstract: Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.
    Type: Application
    Filed: July 1, 2016
    Publication date: March 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, GUY GEORGES, EIKE HOFFMANN, GEORG TIEFENTHALER, EKKEHARD MOESSNER, STEFAN DENGL, ACHIM GAERTNER
  • COVALENTLY LINKED POLYPEPTIDE TOXIN-ANTIBODY CONJUGATES
    Publication number: 20170058051
    Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
    Type: Application
    Filed: July 1, 2016
    Publication date: March 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, EIKE HOFFMANN, STEFAN DENGL, KLAUS MAYER
  • Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
    Patent number: 9574016
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: February 21, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Lau, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXIGENASE (PAM) FOR C-TERMINAL AMIDATION
    Publication number: 20160333386
    Abstract: One aspect as reported herein is a method for in vivo C-terminal amidation of a polypeptide characterized in that both the polypeptide (to be amidated) and human peptidylglycine alpha-amidating monooxigenase (PAM) are recombinantly co-expressed in a mammalian cell.
    Type: Application
    Filed: June 17, 2016
    Publication date: November 17, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: EIKE HOFFMANN, GEORG TIEFENTHALER
  • LIPIDATED INCRETIN RECEPTOR LIGAND HUMAN IMMUNOGLOBULIN FC-REGION FUSION POLYPEPTIDES
    Publication number: 20160310575
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 27, 2016
    Inventors: Sara BELLI, Konrad BLEICHER, Richard D. DIMARCHI, Eike HOFFMANN, Eric A. KITAS, Anish A. KONKAR
  • COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT
    Publication number: 20160009823
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 12, 2014
    Publication date: January 14, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES
    Publication number: 20150258209
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Application
    Filed: December 19, 2014
    Publication date: September 17, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: JOERG BENZ, ULRICH BRINKMANN, STEFAN DENGL, SEBASTIAN DZIADEK, GUY GEORGES, MICHAEL GROTE, ALEXANDER HAAS, EIKE HOFFMANN
  • ANTI-THEOPHYLLINE ANTIBODIES AND METHODS OF USE
    Publication number: 20150238628
    Abstract: The invention provides anti-theophylline antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2014
    Publication date: August 27, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, GUY GEORGES, EIKE HOFFMANN